The U.S. Food and Drug Administration has mandated that manufacturers of weight loss medications like Ozempic and Zepbound include warnings about a rare eye condition called NAION, which can lead to permanent vision loss. GLP-1 drugs, used by approximately 28 million Americans according to a July Gallup poll, increase the risk of this condition.
US is requiring weight-loss drug makers to warn about possible loss of eye sight (this article)2 articles from The Independent on this story